OncoMatch/Clinical Trials/NCT07148050
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Is NCT07148050 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies SC-CAR.GPC3xIL15.21 CAR T cells for solid tumor (excluding cns).
Treatment: SC-CAR.GPC3xIL15.21 CAR T cells — This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibility, and efficacy of administering T cell products derived from peripheral blood mononuclear cells (PBMC) that have been genetically modified to co-express a GPC3-specific chimeric antigen receptor (CAR), interleukin (IL)-15 and IL-21 as well as the inducible caspase 9 (iC9) suicide gene (SC-CAR.GPC3xIL15.21 T cells). A child or young adult meeting all eligibility criteria and meeting none of the exclusion criteria will have a blood sample collected, which will be used to bioengineer the CAR T cells targeting their tumor.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Sarcoma
Rhabdomyosarcoma
Hepatocellular Carcinoma
Biomarker criteria
Required: GPC3 expression
Disease stage
Required: Stage BARCELONA LIVER CANCER STAGE A, BARCELONA LIVER CANCER STAGE B, BARCELONA LIVER CANCER STAGE C (Barcelona Liver Cancer)
Barcelona Liver Cancer Stage A, B or C
Demographics
Prior therapy
Must have received: cytotoxic chemotherapy — up-front therapy and at least one salvage treatment cycle
Refractory or relapsed disease after treatment with up-front therapy and at least one salvage treatment cycle
Lab requirements
Blood counts
Adequate laboratory values
Kidney function
Adequate organ function
Liver function
Child-Pugh Turcotte Score <7
Cardiac function
No congestive heart failure (NYHA III or IV), unstable angina, serious uncontrolled cardiac arrhythmia, myocardial infarction within 6 months, or history of myocarditis
Adequate organ function; Child-Pugh Turcotte Score <7; Adequate laboratory values; Congestive heart failure (as defined by New York Heart Association Functional Classification III or IV), unstable angina, serious uncontrolled cardiac arrhythmia, a myocardial infarction within 6 months prior to study entry or a history of myocarditis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Seattle Children's Hospital · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07148050 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received cytotoxic chemotherapy.
Does this trial require GPC3?
Yes, GPC3 expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage BARCELONA LIVER CANCER STAGE A or BARCELONA LIVER CANCER STAGE B or BARCELONA LIVER CANCER STAGE C is required.
Is there an age limit?
Yes. Patients must be 26 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages